Please assess the completion status of the following clinical trial:

Trial Title: Activity of Mefloquine Against Urinary Schistosomiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women after first trimester and before 28th week of pregnancy~* HIV negative~* Egg excretion of Schistosoma haematobium (mean \>10 eggs per mL urine)~* Asymptomatic (no signs of complicated Schistosomiasis, no severe anemia)~* Ability to comply with study protocol~Exclusion Criteria:~* Intake of anthelminthic or antimalarial drug within 2 months prior to inclusion~* Allergy to study drugs

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mefloquine (Type: EXPERIMENTAL): 15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
- S/P (Type: PLACEBO_COMPARATOR): sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations

Based on this trial design, predict the completion outcome and termination type (if applicable).